Rhinology Journal· 2012Q1· Review
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists
- 1,197citations
- Q1SCImago
- 2012year
Short summary
This summary of the EPOS 2012 guidelines provides evidence-based recommendations for treating rhinosinusitis and nasal polyps, highlighting treatments with limited or no supporting data.
AI-generated from the title and abstract; the full text is not read.
Key points
- Many treatments for rhinosinusitis and nasal polyps lack robust supporting data according to EPOS 2012.
- Topical antibiotics, phytotherapy, decongestants, mucolytics, and antihistamines have limited evidence.
- Systemic and topical antimycotics, anti-leukotrienes, and anti-IgE therapies also show insufficient data.
- Short-term oral antibiotics (<4 weeks) have mixed evidence, leading to a weak recommendation (C).
AI-generated from the title and abstract; the full text is not read.
Abstract
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. no immunosuppressants IV D no nasal saline irrigation Ib, no data in single use D yes for symptomatic relief topical antibiotics no data D no anti-IL-5 no data D unclear phytotherapy no data D no decongestant topical / oral no data in single use D no mucolytics no data D no oral antihistamine in allergic patients no data D no antimycotics -topical Ia (-) ** A(-) no antimycotics -systemic Ib (-)# A(-) $ no anti leukotrienes Ib (-) A(-) no anti-IgE Ib (-) A(-) no * Some of these studies also included patients with CRS with nasal polyps. % short term antibiotics shows one positive and one negative study. Therefore recommendation C. oral antibiotic short term <4 weeks Ib(-) # A(-)* no intravenous antibiotics III(-) ## C(-) ** no # Ib (-): Ib study with a negative outcome.
The authors' abstract, as published at the source. Rhinology Journal, 2012 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Otorhinolaryngology
OtorhinolaryngologyMedicine